Kura Oncology Issues Stock Options to Nine New Hires
Kura Oncology granted inducement stock options covering 128,250 shares to nine new employees, complying with Nasdaq listing rules.
Kura Oncology, Inc. (Nasdaq: KURA) disclosed Thursday that its Compensation Committee authorized inducement stock option grants to nine newly hired employees on October 1, 2026, covering a total of 128,250 shares of common stock.
The awards consist of nonstatutory stock options issued under the San Diego-based biopharmaceutical company's 2023 Inducement Option Plan, as amended. The grants were structured as inducement awards, meaning they are intended to serve as a material incentive for the recipients to accept employment with the company.
Read more Fed Approves Fleur Capital Corporation Bank Application →
Kura Oncology stated the Compensation Committee approved the options in accordance with Nasdaq Listing Rule 5635(c)(4), which permits listed companies to issue equity awards to new employees without prior shareholder approval under certain conditions. The rule is commonly used by publicly traded firms seeking to attract talent through equity compensation.
Kura Oncology describes itself as a precision medicine company focused on developing cancer treatments. Inducement grants of this nature are a standard tool in the biopharmaceutical sector, where equity compensation plays a significant role in recruiting specialized scientific and clinical talent in a competitive labor market.
Continue reading at GlobeNewswire - Mergers And Acquisitions.
